T1	Participants 270 316	patients with CKD, including dialysis patients
T2	Participants 436 585	The Study of Heart and Renal Protection (SHARP) randomized patients with CKD to 20 mg simvastatin plus 10 mg ezetimibe daily versus matching placebo.
